Australia markets close in 3 hours 48 minutes

Aditxt, Inc. (ADTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3800+0.3200 (+10.46%)
At close: 04:00PM EDT
3.3000 -0.08 (-2.37%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0600
Open3.3600
Bid3.3000 x 3000
Ask3.4100 x 1100
Day's range3.2500 - 4.1200
52-week range2.5800 - 136.0000
Volume25,353,847
Avg. volume1,684,370
Market cap3.88M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-1.7200
Earnings date13 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est50.00
  • Business Wire

    Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements

    RICHMOND, Va., September 29, 2022--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel ("Nasdaq") that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), meets the stockholders’ equity requirement

  • Business Wire

    Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering

    RICHMOND, Va., September 27, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today provides shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering.

  • Business Wire

    Aditxt Announces Closing of $20.0 Million Public Offering

    RICHMOND, Va., September 20, 2022--Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the closing of its previously announced public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the publi